Lipid management for the prevention of cardiovascular disease

Current Pharmaceutical Design

Volumn 17, Issue 9, 2011, Pages 852-860

  Schaefer, Juergen R ^a  

^a UNIVERSITY HOSPITAL MARBURG   (Germany)

Author keywords

Atherosclerosis; Coronary artery disease; Lipid lowering therapy; Prevention

Indexed keywords

ATORVASTATIN; COLESEVELAM; COLESTIPOL; COLESTYRAMINE; EZETIMIBE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

ALBUMINURIA; ARTICLE; BRAIN ISCHEMIA; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CORONARY ARTERY BYPASS GRAFT; DIABETES MELLITUS; DRUG EFFICACY; HEART FAILURE; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; HYPERLIPIDEMIA; HYPERTRIGLYCERIDEMIA; KIDNEY DISEASE; MORTALITY; PRIORITY JOURNAL; RETINOPATHY; STROKE; TRANSLUMINAL CORONARY ANGIOPLASTY;

ANTICHOLESTEREMIC AGENTS; CARDIOVASCULAR DISEASES; CHOLESTEROL, LDL; CORONARY ARTERY DISEASE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS;

EID: 79958227268     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/138161211795428849     Document Type: Article

References (63)

1. Schaefer JR, Hufnagel B, Maisch B, Krieglstein J. Why is italways the heart which suffers from myocardial infarction? TheMarburg hypothesis of the pathogenesis of atherosclerosis. Herz 2010; 35(3): 192-7
2. Lichtenstein AH, Appel LJ, Brands M, et al. Diet and LifestyleRecommendations Revision 2006. A Scientific Statement from theAmerican Heart Association Nutrition Committee. Circulation 2006; 114: 82-96.
3. Pekkanen, J, Linn, S, Heiss, G, et al. Ten-year mortality fromcardiovascular disease in relation to cholesterol level among menwith and without preexisting cardiovascular disease. N Engl J Med 1990; 322: 1700-7.
4. Ahmadi N, Hajsadeghi F, Blumenthal RS, Budoff MJ, Stone GW, Ebrahimi R. Mortality in Individuals Without Known Coronary ArteryDisease but With Discordance Between the Framingham RiskScore and Coronary Artery Calcium. Am J Cardiol 2011 Jan 17. [Epub ahead of print]
5. Fitchett DH, Leiter LA, Goodman SG, Langer A. Lower is better:implications of the Treating to New Targets (TNT) study for Canadianpatients. Can J Cardiol 2006; 22(10): 835-9.
6. Nixon JV. Lower is better--the contemporary concept of lowdensitylipoprotein lowering in the preventive management of cardiovascularrisk: does this apply to all patients? Prev Cardiol 2006;9(4): 219-25
7. Cannon CP. The IDEAL cholesterol: lower is better. JAMA 2005;294(19): 2492-4.
8. Wiviott SD, Cannon CP, Morrow DA, Ray KK, Pfeffer MA, Braunwald E. PROVE IT-TIMI 22 Investigators. Can low-densitylipoprotein be too low? The safety and efficacy of achieving verylow low-density lipoprotein with intensive statin therapy: a PROVEIT-TIMI 22 substudy. J Am Coll Cardiol 2005; 46(8): 1411-6.
9. Wei L, MacDonald TM, Watson AD, Murphy MJ. Effectiveness oftwo statin prescribing strategies with respect to adherence and cardiovascularoutcomes: observational study. PharmacoepidemiolDrug Saf 2007; 16(4): 385-92.
10. Donner-Banzhoff N, Sönnichsen A. Statins and primary preventionof cardiovascular events. BMJ 2008; 337: a2576
11. Shepherd J. Statins for primary prevention: strategic options to savelives and money. J R Soc Med 2004; 97(2): 66-71
12. Cholesterol Treatment Trialists' (CTT) Collaboration; Efficacy andsafety of more intensive lowering of LDL cholesterol: a metaanalysisof data from 170 000 participants in 26 randomised trials. Lancet 2010; 376(9753): 1670-1681.
13. Cholesterol Treatment Trialists' (CTT) Collaborators; Efficacy andsafety of cholesterol-lowering treatment: prospective meta-analysisof data from 90 056 participants in 14 randomised trials of statins. Lancet 2005; 366: 1267-78.
14. Randomised trial of cholesterol lowering in 4444 patients withcoronary heart disease: the Scandinavian Simvastatin SurvivalStudy (4S). Lancet 1994; 344: 1383-9.
15. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acutecoronary events with lovastatin in men and women with averagecholesterol levels: results of AFCAPS/TexCAPS. Air Force/TexasCoronary Atherosclerosis Prevention Study. JAMA 1998; 279(20):1615-22.
16. Taylor F, Ward K, Moore THM, et al. Statins for the primaryprevention of cardiovascular disease. Cochrane Database of SystematicReviews 2011, Issue 1. Art. No.: CD004816. DOI:10.1002/14651858.CD004816.pub4.
17. Szucs TD, Guggenberger G, Berger K, März W, Schaefer JR.Pharmacoeconomic evaluation of pravastatin in the secondary preventionof coronary heart disease in patients with average cholesterollevels. An analysis for Germany based on the CARE study. Herz 1998; 23(5): 319-29
18. Szucs TD, Berger K, März W, Schaefer JR. Cost effectiveness ofpravastatin in secondary coronary prevention in patients with myocardialinfarct or unstable angina in Germany. An analysis on thebasis of the LIPID trial. Herz 2000; 25(5): 487-94.
19. Szucs TD. Pharmaco-economic aspects of lipid-lowering therapy:is it worth the price? Eur Heart J 1998; 19 Suppl M: M22-8.
20. Rosenson RS, Baker SK. Muscle injury with lipid lowering drugs. In: UpToDate, Freeman M.W. (section editor) and Basow D.S. (ed)UpToDate, Waltham, MA 2011, USA
21. Rosenson RS. Treatment of lipids (including hypercholesterolemia)in secondary prevention. In: UpToDate, Freeman M.W. (sectioneditor) and Basow D.S. (ed) UpToDate, Waltham, MA 2011, USA
22. Cannon, CP, Braunwald, E, McCabe, CH, et al. Intensive versusmoderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004; 350: 1495-504.
23. Ostadal P, Alan D, Vejvoda J. Statins in the first-line therapy ofacute coronary syndrome - similar to aspirin? Exp Clin Cardiol 2005; 10(1): 9-16.
24. de Lemos, JA, Blazing, MA, Wiviott, SD, et al. Early intensive vsa delayed conservative simvastatin strategy in patients with acutecoronary syndromes: phase Z of the A to Z trial. JAMA 2004; 292:1307-16.
25. Pineda A, Cubeddu LX. Statin rebound or withdrawal syndrome:does it exist? Curr Atheroscler Rep 2011; 13(1): 23-30.
26. Heeschen C, Hamm CW, Laufs U, Snapinn S, Böhm M, WhiteHD. Platelet Receptor Inhibition in Ischemic Syndrome Management(PRISM) Investigators. Withdrawal of statins increases eventrates in patients with acute coronary syndromes. Circulation 2002;105(12): 1446-52.
27. Spencer FA, Fonarow GC, Frederick PD, et al. National Registryof Myocardial Infarction; Early withdrawal of statin therapy in patientswith non-ST-segment elevation myocardial infarction: nationalregistry of myocardial infarction. Arch Intern Med 2004;164(19): 2162-8.
28. Shepherd J, Hunninghake DB, Barter P, McKenney JM, Hutchinson HG. Guidelines for lowering lipids to reduce coronaryartery disease risk: a comparison of rosuvastatin with atorvastatin,pravastatin, and simvastatin for achieveng lipid-lowering goals. AmJ Cardiol 2003; 91(5A): 11C-17C
29. Dujovne CA, Williams CD, Ito MK. What combination therapywith a statin, if any, would you recommend? Curr Atheroscler Rep 2011; 13(1): 12-22.
30. Pearson TA, Denke MA, McBride PE, Battisti WP, Brady WE, Palmisano J. A community-based, randomized trial of ezetimibeadded to statin therapy to attain NCEP ATP III goals for LDL cholesterolin hypercholesterolemic patients: the ezetimibe add-on tostatin for effectiveness (EASE) trial. Mayo Clin Proc 2005; 80(5):587-95
31. Mikhailidis DP, Sibbring GC, Ballantyne CM, Davies GM, CatapanoAL. Meta-analysis of the cholesterol-lowering effect ofezetimibe added to ongoing statin therapy. Curr Med Res Opin 2007; 23(8): 2009-26
32. Kastelein JJ, Akdim F, Stroes ES, et al. ENHANCE Investigators.Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med 2008; 358(14): 1431-43
33. Rossebø AB, Pedersen TR, Boman K, et al. SEAS Investigators.Intensive lipid lowering with simvastatin and ezetimibe in aorticstenosis. N Engl J Med 2008; 359(13): 1343-56.
34. Gerdts E, Rossebø AB, Pedersen TR, et al. Impact of baselineseverity of aortic valve stenosis on effect of intensive lipid loweringtherapy (from the SEAS study). Am J Cardiol 2010; 106(11):1634-9.
35. Holme I, Boman K, Brudi P, et al. Observed and predicted reductionof ischemic cardiovascular events in the Simvastatin andEzetimibe in Aortic Stenosis trial. Am J Cardiol 2010; 105(12):1802-8.
36. Baigent C, Landray M, SHARP investigators (2010) The results ofthe Study of Heart and Renal Protection (SHARP) http://www.ctsu.ox.ac.uk/~sharp/slides.htm (accessed 01.March.2011)
37. Gille A, Bodor ET, Ahmed K, Offermanns S. Nicotinic acid:pharmacological effects and mechanisms of action. Annu RevPharmacol Toxicol 2008; 48: 79-106.
38. Vittone F, Chait A, Morse JS, Fish B, Brown BG, Zhao XQ. Niacinplus Simvastatin Reduces Coronary Stenosis Progression AmongPatients with Metabolic Syndrome Despite a Modest Increase inInsulin Resistance: A Subgroup Analysis of the HDLAtherosclerosisTreatment Study (HATS). J Clin Lipidol 2007;1(3): 203-210.
39. Zhao XQ, Krasuski RA, Baer J, et al. Effects of combination lipidtherapy on coronary stenosis progression and clinical cardiovascularevents in coronary disease patients with metabolic syndrome: acombined analysis of the Familial Atherosclerosis Treatment Study(FATS), the HDL-Atherosclerosis Treatment Study (HATS), andthe Armed Forces Regression Study (AFREGS). Am J Cardiol 2009; 104(11): 1457-64.
40. The Lipid Research Clinics Coronary Primary Prevention Trialresults. I. Reduction in incidence of coronary heart disease. JAMA 1984; 251(3): 351-64
41. Avitabile N, Banka A, Fonseca VA. Safety evaluation of colesevelamtherapy to achieve glycemic and lipid goals in type 2 diabetes. Expert Opin Drug Saf 2011 Jan 19. [Epub ahead of print]
42. Insull W Jr, Toth P, Mullican W, et al. Effectiveness of colesevelamhydrochloride in decreasing LDL cholesterol in patients withprimary hypercholesterolemia: a 24-week randomized controlledtrial. Mayo Clin Proc 2001; 76(10): 971-82.
43. Brunetti L, Hermes-Desantis ER. The role of colesevelam hydrochloridein hypercholesterolemia and type 2 diabetes mellitus. AnnPharmacother 2010; 44(7-8): 1196-206.
44. Aldridge MA, Ito MK. Colesevelam hydrochloride: a novel bileacid-binding resin. Ann Pharmacother 2001; 35(7-8): 898-907.
45. Huijgen R, Abbink EJ, Bruckert E, et al. Triple Study Group. Colesevelam added to combination therapy with a statin andezetimibe in patients with familial hypercholesterolemia: a 12-week, multicenter, randomized, double-blind, controlled trial. ClinTher 2010; 32(4): 615-25.
46. ACCORD Study Group, Ginsberg HN, Elam MB, Lovato LC, et al. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 2010; 362(17): 1563-74.
47. Colhoun HM, Betteridge DJ, Durrington PN, et al. CARDS investigators.Primary prevention of cardiovascular disease with atorvastatinin type 2 diabetes in the Collaborative Atorvastatin DiabetesStudy (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004; 364(9435): 685-96.
48. Cholesterol Treatment Trialists' (CTT), Collaborators, KearneyPM, Blackwell L, et al. Efficacy of cholesterol-lowering therapy in18,686 people with diabetes in 14 randomised trials of statins: ameta-analysis. Lancet 2008; 371: 117-25.
49. Rajpathak SN, Kumbhani DJ, Crandall J, Barzilai N, Alderman M, Ridker PM. Statin therapy and risk of developing type 2 diabetes: ameta-analysis. Diabetes Care 2009; 32(10): 1924-9.
50. Sattar N, Preiss D, Murray HM, et al. Statins and risk of incidentdiabetes: a collaborative meta-analysis of randomised statin trials. Lancet 2010; 375(9716): 735-42.
51. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatinon coronary events after myocardial infarction in patients with averagecholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996; 335: 1001-9.
52. Heart Protection Study Collaborative Group. MRC/BHF HeartProtection Study of cholesterol lowering with simvastatin in 20,536high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360: 7-22.
53. Shepherd J, Blauw GJ, Murphy MB, Bollen EL, et al. PROSPERstudy group. PROspective Study of Pravastatin in the Elderly atRisk; Pravastatin in elderly individuals at risk of vascular disease(PROSPER): a randomised controlled trial. Lancet 2002;360(9346): 1623-30
54. Bang LM, Goa KL. Pravastatin: a review of its use in elderlypatients. Drugs Aging 2003; 20(14): 1061-82.
55. EJ Jacobs, CC Newton, MJ Thun, SM. Gapstur; Long-term use ofcholesterol-lowering drugs and cancer incidence in a large UnitedStates Cohort. Cancer Res 2011; 71(5): 1763-71
56. Zhang L, Zhang S, Jiang H, Sun A, Zou Y, Ge J. Effects of StatinTreatment on Cardiac Function in Patients With Chronic HeartFailure: A Meta-Analysis of Randomized Controlled Trials. ClinCardiol 2010 Dec 10. [Epub ahead of print]
57. Laufs U, Custodis F, Böhm M. HMG-CoA reductase inhibitors inchronic heart failure: potential mechanisms of benefit and risk. Drugs 2006; 66(2): 145-54.
58. Lyons KS, McVeigh GE, Harbinson MT. Statins in Heart Failure-Where Do We Stand? Cardiovasc Drugs Ther 2010 Dec 7. [Epubahead of print]
59. Kjekshus J, Apetrei E, Barrios V, et al. CORONA Group. Rosuvastatinin older patients with systolic heart failure. N Engl J Med2007; 357(22): 2248-61.
60. Navaneethan SD, Pansini F, Perkovic V, et al. HMG CoA reductaseinhibitors (statins) for people with chronic kidney disease notrequiring dialysis. Cochrane Database Syst Rev 2009 Apr 15; (2):CD007784.
61. Wanner C, Krane V, März W, et al. German Diabetes and DialysisStudy Investigators. Atorvastatin in patients with type 2 diabetesmellitus undergoing hemodialysis. N Engl J Med 2005; 353(3):238-48.
62. Fellström BC, Jardine AG, Schmieder RE, et al. AURORA StudyGroup. Rosuvastatin and cardiovascular events in patients undergoinghemodialysis. N Engl J Med 2009; 360(14): 1395-407.
63. Krane V, Krieter DH, Olschewski M, et al. Dialyzer membranecharacteristics and outcome of patients with type 2 diabetes onmaintenance hemodialysis. Am J Kidney Dis 2007; 49(2): 267-75.